Intact Investment Management Inc. boosted its position in shares of Mylan NV (NASDAQ:MYL) by 66.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,500 shares of the company’s stock after purchasing an additional 5,800 shares during the period. Intact Investment Management Inc.’s holdings in Mylan were worth $531,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. First Mercantile Trust Co. purchased a new stake in Mylan in the 2nd quarter valued at about $121,000. CENTRAL TRUST Co boosted its position in Mylan by 1,057.8% in the 2nd quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock valued at $188,000 after buying an additional 4,760 shares during the period. FTB Advisors Inc. purchased a new stake in Mylan in the 2nd quarter valued at about $188,000. Reilly Financial Advisors LLC boosted its position in Mylan by 69.4% in the 3rd quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock valued at $191,000 after buying an additional 2,137 shares during the period. Finally, BB&T Corp purchased a new stake in Mylan in the 3rd quarter valued at about $202,000. Institutional investors own 82.91% of the company’s stock.
Several equities research analysts have issued reports on MYL shares. BidaskClub cut shares of Mylan from a “hold” rating to a “sell” rating in a research report on Friday, July 13th. Wells Fargo & Co reissued a “hold” rating on shares of Mylan in a research report on Wednesday, July 25th. ValuEngine raised shares of Mylan from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd. Mizuho reissued a “buy” rating and issued a $54.00 price objective on shares of Mylan in a research report on Wednesday, August 8th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $41.00 price objective on shares of Mylan in a research report on Wednesday, August 8th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company. Mylan presently has a consensus rating of “Hold” and an average target price of $47.73.
Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 8th. The company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.15). Mylan had a return on equity of 18.48% and a net margin of 3.90%. The business had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.95 billion. During the same period in the previous year, the company posted $1.10 EPS. Mylan’s revenue for the quarter was down 5.2% on a year-over-year basis. As a group, equities analysts expect that Mylan NV will post 4.62 EPS for the current year.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Featured Story: Insider Trading – What You Need to Know
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.